WALTHAM, Mass.– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that South Korea–based Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO), has selected Thermo Fisher to equip its new manufacturing facility with advanced bioprocessing technologies.
Dr. Park specializes in adeno-associated virus (AAV)–based vector production and currently produces 5,000 liters per batch, generating up to 40 clinical-grade batches annually. The company inaugurated its new Phase 1 facility on August 5, 2025, with plans to achieve current Good Manufacturing Practice (cGMP) certification in 2026 and further expand its capacity to 10,000 liters per batch.
The new site has been outfitted with Thermo Fisher’s HyPerforma 1,000 L Single-Use Bioreactor, Thermo Scientific Nunc Automated Cell Factory Manipulator and Thermo Scientific DynaSpin Single-Use Centrifuge. These integrated solutions are designed to streamline both upstream and downstream processes, reduce manual interventions and support efficient scale-up from clinical to commercial manufacturing. By enhancing process control and automation, the technologies will improve efficiency, scalability and consistency while ensuring high standards of safety, quality and regulatory compliance.
“We are proud to collaborate with Dr. Park CDMO as they advance viral vector manufacturing in South Korea,” said Daniella Cramp, Senior Vice President and President of BioProduction at Thermo Fisher Scientific. “By providing our reliable and scalable bioprocessing solutions, we aim to speed up development and delivery of cell and gene therapies to patients who need them.”
Yong-Ho Park, CEO of Dr. Park, said: “Our collaboration with Thermo Fisher Scientific has been instrumental in equipping our new facility with advanced bioproduction capabilities. Their cutting-edge technologies and deep expertise are critical enablers of our long-term vision and will strengthen our ability to serve customers globally.”
Tony Acciarito, President for Asia Pacific and the Middle East and Africa at Thermo Fisher Scientific, added: “Collaboration is essential in advancing scientific innovation and bringing new therapies to patients. Our work with Dr. Park CDMO reflects a shared commitment to building robust manufacturing capabilities in South Korea and across the region. By working together, we can progress cell and gene therapies and support the evolving needs of the industry.”
